• Entertainment
  • Finance
  • Marketing
  • Real Estate
  • Technology
  • Social
National Journal Community Of e-Experts
Finance 0

NewLink Genetics Plunges After Competitor IDO Drug Fails In Trial

By Kurt Osterberg · On April 6, 2018

Shares of NewLink Genetics (NLNK), a clinical-stage company focused on developing and commercializing immunotherapeutic products for the treatment of cancer, plunged in pre-market trading after a competitor exploring the same areas of cancer treatment reported a clinical trial that did not succeed in achieving its goal.

Incyte/Merck Combo Misses Mark

Incyte (INCY) and partner Merck (MRK) announced this morning that an external Data Monitoring Committee, or eDMC, review of the pivotal Phase 3 ECHO-301/KEYNOTE-252 study results evaluating Incyte’s epacadostat in combination with Merck’s Keytruda in patients with unresectable or metastatic melanoma determined that the study did not meet the primary endpoint of improving progression-free survival in the overall population compared to Keytruda monotherapy.

Epacadostat belongs to a class of drugs called IDO inhibitors. NewLink’s Indoximod is an investigational, orally available small molecule targeting the IDO pathway.

Nektar Down Too

Shares of Nektar Therapeutics (NKTR), whose clinical programs include immuno-oncology and immunology are also sliding this morning. Adam Feuerstein of STAT has tweeted this morning: “$NKTR is the new $INCY. Anyone worried about that now?”

Price Action 

In pre-market trading, Nektar shares were down about 6%; Incyte down 21%; and NewLink  plunged about 37.5%.

 

Print Friendly, PDF & Email

Share Tweet

Kurt Osterberg

You Might Also Like

  • Finance

    Becoming a More Decisive Leader

  • Finance

    Let’s Talk About the “F” Word: Feedback

  • Finance

    7 Tips to Increase Productivity When Working From Home

No Comments

Leave a reply Cancel reply

Top Finance

  • Chart: Amazon’s Dominance In Ecommerce Chart: Amazon’s Dominance In Ecommerce
  • Hedge Funds In The US Hedge Funds In The US
  • One Ring To Rule Them All One Ring To Rule Them All
  • Kanban vs Scrum: Understanding the Tools for Agile Success Kanban vs Scrum: Understanding the Tools for Agile Success
  • Samsung Galaxy Note 9 Review Samsung Galaxy Note 9 Review

New Posts

  • Becoming a More Decisive Leader

    Becoming a More Decisive Leader

    February 28, 2021
  • Let’s Talk About the “F” Word: Feedback

    Let’s Talk About the “F” Word: Feedback

    February 28, 2021
  • 7 Tips to Increase Productivity When Working From Home

    7 Tips to Increase Productivity When Working From Home

    February 27, 2021
  • The Door’s Open but the Ride It Ain’t Free

    The Door’s Open but the Ride It Ain’t Free

    February 27, 2021
  • 5 Smart Ways to Improve Your ROI (Plus Tools & Templates)

    5 Smart Ways to Improve Your ROI (Plus Tools & Templates)

    February 27, 2021
  • About
  • Contact Us
  • Privacy & Policy
  • Sitemap
  • Terms of use

Copyright © 2018-2021 NJCEE. All Rights Reserved.